Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Cancer Group, China
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Center for International Blood and Marrow Transplant Research
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc.
European Myeloma Network B.V.
Merck Sharp & Dohme LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Spanish Breast Cancer Research Group
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
USWM, LLC (dba US WorldMeds)
Hoffmann-La Roche
M.D. Anderson Cancer Center
Celgene
Ohio State University Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
St. Jude Children's Research Hospital
Allogene Therapeutics
Genmab
National Cancer Institute (NCI)
Genmab
Genmab
Emory University
Case Comprehensive Cancer Center
USWM, LLC (dba US WorldMeds)
M.D. Anderson Cancer Center
USWM, LLC (dba US WorldMeds)
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Children's Oncology Group
University of Pennsylvania
St. Jude Children's Research Hospital
AstraZeneca
Novartis
Merck Sharp & Dohme LLC
Dartmouth-Hitchcock Medical Center